Recent studies have focused on the overlap of GLP-1|glucose-dependent insulinotropic polypeptide|GCGR activator therapies and dopamine neurotransmission. While GCGR agonists are commonly employed for managing type 2 diabetes, their emerging effects on reward circuits, specifically mediated by dop